Pediatric Hemispheric High-Grade Gliomas and H3.3-G34 Mutation: A Review of the Literature on Biological Features and New Therapeutic Strategies
Genes · 2024
DOI: 10.3390/genes15081038 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, 2024. Verfasst von Marta Bonada und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133 Milan, Italy. Hauptthemen laut MEDLINE: Glioma, Mutation, Brain Neoplasms, Histones. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 194 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pediatric high-grade glioma (pHGG) encompasses a wide range of gliomas with different genomic, epigenomic, and transcriptomic features. Almost 50% of pHGGs present a mutation in genes coding for histone 3, including the subtype harboring the H3.3-G34 mutation. In this context, histone mutations are frequently associated with mutations in TP53 and ATRX, along with PDGFRA and NOTCH2NL amplifications. Moreover, the H3.3-G34 histone mutation induces epigenetic changes in immune-related genes and exerts modulatory functions on the microenvironment. Also, the functionality of the blood–brain barrier (BBB) has an impact on treatment response. The prognosis remains poor with conventional treatments, thus eliciting the investigation of additional and alternative therapies. Promising molecular targets include PDGFRA amplification, BRAF mutation, EGFR amplification, NF1 loss, and IDH mutation. Considering that pHGGs harboring the H3.3-G34R mutation appear to be more susceptible to immunotherapies (ITs), different options have been recently explored, including immune checkpoint inhibitors, antibody mediated IT, and Car-T cells. This review aims to summarize the knowledge concerning cancer biology and cancer-immune cell interaction in this set of pediatric gliomas, with a focus on possible therapeutic options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133 Milan, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan School of Medicine, Via Rudini 8, 20122 Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, 20072 Milan, Italy.
- Department of Medicine, Vita-Salute San Raffaele University School of Medicine, 20132 Milan, Italy.
- ASST Ovest Milanese, Neurology and Stroke Unit, Neuroscience Department, 20025 Legnano, Italy.
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120, USA.
ORCID-Profile: Matilde Pittarello, Alessandro Gans, Hasan Slika, Federico Legnani, Francesco Di Meco, Betty Tyler
Zitieren
APA
Bonada, M., Pittarello, M., De Fazio, E., Gans, A., Alimonti, P., Slika, H., Legnani, F., Di Meco, F., & Tyler, B. (2024). Pediatric Hemispheric High-Grade Gliomas and H3.3-G34 Mutation: A Review of the Literature on Biological Features and New Therapeutic Strategies. Genes. https://doi.org/10.3390/genes15081038
Vancouver
Bonada M, Pittarello M, De Fazio E, Gans A, Alimonti P, Slika H, et al. Pediatric Hemispheric High-Grade Gliomas and H3.3-G34 Mutation: A Review of the Literature on Biological Features and New Therapeutic Strategies. Genes. 2024. doi:10.3390/genes15081038
BibTeX
@article{Bonada2024,
author = {Bonada, Marta and Pittarello, Matilde and De Fazio, Emerson and Gans, Alessandro and Alimonti, Paolo and Slika, Hasan and Legnani, Federico and Di Meco, Francesco and Tyler, Betty},
title = {Pediatric Hemispheric High-Grade Gliomas and H3.3-G34 Mutation: A Review of the Literature on Biological Features and New Therapeutic Strategies},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15081038}
}
EUVIMED